Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Aprea Therapeutics, Inc.

APRE Nasdaq SEC CIK 1781983
Follow Aprea Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$3.6M −10.9% vs same quarter last year
EPS, diluted −$0.07 +86.8% vs same quarter last year
Operating cash flow −$3.3M −4.7% vs same quarter last year
Operating income −$4M −19% vs same quarter last year
Net income by quarter
−$3.8M
−$2.9M
−$3.9M
−$3.2M
−$3M
−$2.5M
−$3.3M
−$3.6M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
−$150M−$100M−$50M$0FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$12.6M
FY24−$13M
FY23−$14.3M
FY22−$112.7M
FY21−$37.1M
FY20−$53.5M
FY19−$28.1M
FY18−$15.5M
FY17−$15.2M
FY16-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$13.6M
FY23−$12.3M
FY22-
FY21-
FY20−$41.8M
FY19−$26.7M
FY18−$15.3M
FY17-
FY16-

News

No stories filed under Aprea Therapeutics yet - coverage appears here as the news feed clusters it.